JP2022515520A - 神経変性障害を処置するための組成物及び処置する方法 - Google Patents
神経変性障害を処置するための組成物及び処置する方法 Download PDFInfo
- Publication number
- JP2022515520A JP2022515520A JP2021538053A JP2021538053A JP2022515520A JP 2022515520 A JP2022515520 A JP 2022515520A JP 2021538053 A JP2021538053 A JP 2021538053A JP 2021538053 A JP2021538053 A JP 2021538053A JP 2022515520 A JP2022515520 A JP 2022515520A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- phenyl
- benzoic acid
- acid
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims description 22
- 208000015122 neurodegenerative disease Diseases 0.000 title description 3
- 241001465754 Metazoa Species 0.000 claims abstract description 42
- 150000003839 salts Chemical class 0.000 claims abstract description 33
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 26
- -1 5-benzylaminosalicylic acid compound Chemical class 0.000 claims abstract description 14
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 14
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 9
- 208000024732 dysthymic disease Diseases 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 24
- 230000001149 cognitive effect Effects 0.000 claims description 18
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 18
- 125000003118 aryl group Chemical group 0.000 claims description 17
- 208000035475 disorder Diseases 0.000 claims description 17
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 230000003188 neurobehavioral effect Effects 0.000 claims description 16
- UGCLFNDSMFHCBO-UHFFFAOYSA-N 5-(benzylamino)-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCC=2C=CC=CC=2)=C1 UGCLFNDSMFHCBO-UHFFFAOYSA-N 0.000 claims description 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- UTMVACIBQLDZLP-UHFFFAOYSA-N crisdesalazine Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C=CC(=CC=2)C(F)(F)F)=C1 UTMVACIBQLDZLP-UHFFFAOYSA-N 0.000 claims description 12
- 230000036542 oxidative stress Effects 0.000 claims description 11
- 239000005711 Benzoic acid Substances 0.000 claims description 10
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 10
- 235000013305 food Nutrition 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical class 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 239000011575 calcium Substances 0.000 claims description 9
- 229910052791 calcium Inorganic materials 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 9
- 235000015872 dietary supplement Nutrition 0.000 claims description 9
- 230000005764 inhibitory process Effects 0.000 claims description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims description 9
- 235000019750 Crude protein Nutrition 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 235000019784 crude fat Nutrition 0.000 claims description 8
- 239000000835 fiber Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- 239000007910 chewable tablet Substances 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 235000010233 benzoic acid Nutrition 0.000 claims description 5
- 230000037396 body weight Effects 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims description 4
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims description 4
- 239000004475 Arginine Substances 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 4
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
- 239000004472 Lysine Substances 0.000 claims description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229960004909 aminosalicylic acid Drugs 0.000 claims description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 4
- 230000003778 catagen phase Effects 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 235000010980 cellulose Nutrition 0.000 claims description 4
- 229940068682 chewable tablet Drugs 0.000 claims description 4
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 229960003067 cystine Drugs 0.000 claims description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 229960001021 lactose monohydrate Drugs 0.000 claims description 4
- 229930182817 methionine Natural products 0.000 claims description 4
- 210000001589 microsome Anatomy 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 239000000377 silicon dioxide Substances 0.000 claims description 4
- 235000012239 silicon dioxide Nutrition 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 239000004334 sorbic acid Substances 0.000 claims description 4
- 235000010199 sorbic acid Nutrition 0.000 claims description 4
- 229940075582 sorbic acid Drugs 0.000 claims description 4
- XDMMJIGHNYLDPB-UHFFFAOYSA-N 2-acetyloxy-5-[2-[4-(trifluoromethyl)phenyl]ethylamino]benzoic acid Chemical compound C1=C(C(O)=O)C(OC(=O)C)=CC=C1NCCC1=CC=C(C(F)(F)F)C=C1 XDMMJIGHNYLDPB-UHFFFAOYSA-N 0.000 claims description 3
- CJJCDRXAYMJUBC-UHFFFAOYSA-N 2-aminooxy-5-[(2,3,4,5,6-pentafluorophenyl)methyl]benzoic acid Chemical compound FC1=C(C(=C(C(=C1CC1=CC=C(C(C(=O)O)=C1)ON)F)F)F)F CJJCDRXAYMJUBC-UHFFFAOYSA-N 0.000 claims description 3
- TVEAFEPGWCRJEZ-UHFFFAOYSA-N 2-aminooxy-5-[2-(4-nitrophenyl)ethyl]benzoic acid Chemical compound C1=C(C(O)=O)C(ON)=CC=C1CCC1=CC=C([N+]([O-])=O)C=C1 TVEAFEPGWCRJEZ-UHFFFAOYSA-N 0.000 claims description 3
- JSJGDVGFCIWRKT-UHFFFAOYSA-N 2-aminooxy-5-[[4-(trifluoromethyl)phenyl]methyl]benzoic acid Chemical compound C1=C(C(O)=O)C(ON)=CC=C1CC1=CC=C(C(F)(F)F)C=C1 JSJGDVGFCIWRKT-UHFFFAOYSA-N 0.000 claims description 3
- TYPVQMDBCHPIFE-UHFFFAOYSA-N 2-hydroxy-5-(2-phenylethylamino)benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C=CC=CC=2)=C1 TYPVQMDBCHPIFE-UHFFFAOYSA-N 0.000 claims description 3
- LSMVCKYIWJNDNV-UHFFFAOYSA-N 2-hydroxy-5-(3-phenylpropylamino)benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCCC=2C=CC=CC=2)=C1 LSMVCKYIWJNDNV-UHFFFAOYSA-N 0.000 claims description 3
- LNDYNJBZIIMHKN-UHFFFAOYSA-N 2-hydroxy-5-[(4-methoxyphenyl)methylamino]benzoic acid Chemical compound C1=CC(OC)=CC=C1CNC1=CC=C(O)C(C(O)=O)=C1 LNDYNJBZIIMHKN-UHFFFAOYSA-N 0.000 claims description 3
- XPZYHRSDEFWWSL-UHFFFAOYSA-N 2-hydroxy-5-[(4-nitrobenzoyl)amino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NC(=O)C=2C=CC(=CC=2)[N+]([O-])=O)=C1 XPZYHRSDEFWWSL-UHFFFAOYSA-N 0.000 claims description 3
- MEOMKGGNUSFYCD-UHFFFAOYSA-N 2-hydroxy-5-[(4-nitrophenyl)methylamino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCC=2C=CC(=CC=2)[N+]([O-])=O)=C1 MEOMKGGNUSFYCD-UHFFFAOYSA-N 0.000 claims description 3
- JPGZAIYCPCKDLB-UHFFFAOYSA-N 2-hydroxy-5-[2-(2-nitrophenyl)ethylamino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C(=CC=CC=2)[N+]([O-])=O)=C1 JPGZAIYCPCKDLB-UHFFFAOYSA-N 0.000 claims description 3
- UGNUPSVXVHLMDS-UHFFFAOYSA-N 2-hydroxy-5-[2-(4-methoxyphenyl)ethylamino]benzoic acid Chemical compound C1=CC(OC)=CC=C1CCNC1=CC=C(O)C(C(O)=O)=C1 UGNUPSVXVHLMDS-UHFFFAOYSA-N 0.000 claims description 3
- QFBIFDABMNWMRA-UHFFFAOYSA-N 2-hydroxy-5-[2-[3-(trifluoromethyl)phenyl]ethylamino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C=C(C=CC=2)C(F)(F)F)=C1 QFBIFDABMNWMRA-UHFFFAOYSA-N 0.000 claims description 3
- CMGSFYWEHNDRRO-UHFFFAOYSA-N 2-hydroxy-5-[3-(4-methylphenyl)propylamino]benzoic acid Chemical compound C1=CC(C)=CC=C1CCCNC1=CC=C(O)C(C(O)=O)=C1 CMGSFYWEHNDRRO-UHFFFAOYSA-N 0.000 claims description 3
- YWRQYUUZJRYBKN-UHFFFAOYSA-N 5-[(4-fluorophenyl)methylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCC=2C=CC(F)=CC=2)=C1 YWRQYUUZJRYBKN-UHFFFAOYSA-N 0.000 claims description 3
- PWTQUXPDNFVFIB-UHFFFAOYSA-N 5-[2-(2-chlorophenyl)ethylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C(=CC=CC=2)Cl)=C1 PWTQUXPDNFVFIB-UHFFFAOYSA-N 0.000 claims description 3
- NELHLGXTKKBRCE-UHFFFAOYSA-N 5-[2-(3,4-dichlorophenyl)ethylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C=C(Cl)C(Cl)=CC=2)=C1 NELHLGXTKKBRCE-UHFFFAOYSA-N 0.000 claims description 3
- IGELZLIAULWPMC-UHFFFAOYSA-N 5-[2-(3,4-difluorophenyl)ethylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C=C(F)C(F)=CC=2)=C1 IGELZLIAULWPMC-UHFFFAOYSA-N 0.000 claims description 3
- AXALMYVESXLTTF-UHFFFAOYSA-N 5-[2-(4-chlorophenyl)ethylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C=CC(Cl)=CC=2)=C1 AXALMYVESXLTTF-UHFFFAOYSA-N 0.000 claims description 3
- PKARRJLGDWBPBA-UHFFFAOYSA-N 5-[2-[2-fluoro-4-(trifluoromethyl)phenyl]ethylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C(=CC(=CC=2)C(F)(F)F)F)=C1 PKARRJLGDWBPBA-UHFFFAOYSA-N 0.000 claims description 3
- DVMACQINJNAKQN-UHFFFAOYSA-N 5-[3-(4-fluorophenyl)propylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCCC=2C=CC(F)=CC=2)=C1 DVMACQINJNAKQN-UHFFFAOYSA-N 0.000 claims description 3
- 241000287828 Gallus gallus Species 0.000 claims description 3
- 102000004226 Prostaglandin-E Synthases Human genes 0.000 claims description 3
- 108090000748 Prostaglandin-E Synthases Proteins 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- DINKPILNIKHAAM-UHFFFAOYSA-N 3-acetamido-2-(2-acetyloxyethyl)-5-[(4-nitrophenyl)methyl]benzoic acid Chemical compound CC(=O)NC1=CC(=CC(=C1CCOC(=O)C)C(=O)O)CC2=CC=C(C=C2)[N+](=O)[O-] DINKPILNIKHAAM-UHFFFAOYSA-N 0.000 claims description 2
- AEDBPOPSLDSBMP-UHFFFAOYSA-N 2-hydroxy-5-[3-(4-nitrophenyl)propylamino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCCC=2C=CC(=CC=2)[N+]([O-])=O)=C1 AEDBPOPSLDSBMP-UHFFFAOYSA-N 0.000 claims 2
- VNKBKWSRMXEWHM-UHFFFAOYSA-N 2-hydroxy-5-[3-[4-(trifluoromethyl)phenyl]propylamino]benzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCCC=2C=CC(=CC=2)C(F)(F)F)=C1 VNKBKWSRMXEWHM-UHFFFAOYSA-N 0.000 claims 2
- LOHHDUQMXAYMSQ-UHFFFAOYSA-N 5-[(4-chlorophenyl)methylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCC=2C=CC(Cl)=CC=2)=C1 LOHHDUQMXAYMSQ-UHFFFAOYSA-N 0.000 claims 2
- OCRMFXZJQWNERJ-UHFFFAOYSA-N 5-[2-[3,5-bis(trifluoromethyl)phenyl]ethylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)=C1 OCRMFXZJQWNERJ-UHFFFAOYSA-N 0.000 claims 2
- ALBUSZMBUNQOGZ-UHFFFAOYSA-N 5-[2-[4-fluoro-2-(trifluoromethyl)phenyl]ethylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCC=2C(=CC(F)=CC=2)C(F)(F)F)=C1 ALBUSZMBUNQOGZ-UHFFFAOYSA-N 0.000 claims 2
- ITJHWZWPRLEEKE-UHFFFAOYSA-N 5-[3-(3,4-dichlorophenyl)propylamino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC(NCCCC=2C=C(Cl)C(Cl)=CC=2)=C1 ITJHWZWPRLEEKE-UHFFFAOYSA-N 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 abstract description 8
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 7
- 208000025966 Neurological disease Diseases 0.000 abstract description 6
- 230000003001 depressive effect Effects 0.000 abstract description 3
- 208000028698 Cognitive impairment Diseases 0.000 abstract description 2
- 230000000750 progressive effect Effects 0.000 abstract description 2
- 238000010586 diagram Methods 0.000 abstract 1
- 241000282472 Canis lupus familiaris Species 0.000 description 69
- 229940125782 compound 2 Drugs 0.000 description 59
- 125000000217 alkyl group Chemical group 0.000 description 29
- 238000011282 treatment Methods 0.000 description 26
- 230000006399 behavior Effects 0.000 description 17
- 241000282465 Canis Species 0.000 description 16
- 125000001424 substituent group Chemical group 0.000 description 16
- 230000003542 behavioural effect Effects 0.000 description 15
- 208000024827 Alzheimer disease Diseases 0.000 description 14
- 241000282326 Felis catus Species 0.000 description 14
- 208000024891 symptom Diseases 0.000 description 14
- 230000029142 excretion Effects 0.000 description 13
- 125000003545 alkoxy group Chemical group 0.000 description 12
- 230000015654 memory Effects 0.000 description 12
- 230000009286 beneficial effect Effects 0.000 description 10
- 230000003920 cognitive function Effects 0.000 description 10
- 210000004498 neuroglial cell Anatomy 0.000 description 10
- 230000003997 social interaction Effects 0.000 description 10
- 230000002829 reductive effect Effects 0.000 description 9
- 206010013395 disorientation Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000902 placebo Substances 0.000 description 8
- 229940068196 placebo Drugs 0.000 description 8
- 230000011273 social behavior Effects 0.000 description 8
- 125000002252 acyl group Chemical group 0.000 description 7
- 208000004209 confusion Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 230000004796 pathophysiological change Effects 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 5
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 5
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 5
- 206010003694 Atrophy Diseases 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000282324 Felis Species 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 5
- 230000037444 atrophy Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000001183 hydrocarbyl group Chemical group 0.000 description 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 150000002894 organic compounds Chemical class 0.000 description 5
- 230000008447 perception Effects 0.000 description 5
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 5
- 229960003946 selegiline Drugs 0.000 description 5
- 230000008454 sleep-wake cycle Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 125000004414 alkyl thio group Chemical group 0.000 description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000003376 axonal effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000001589 carboacyl group Chemical group 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 229940124530 sulfonamide Drugs 0.000 description 4
- 150000003456 sulfonamides Chemical class 0.000 description 4
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 3
- 206010012305 Demyelination Diseases 0.000 description 3
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 3
- 206010021703 Indifference Diseases 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 208000012898 Olfaction disease Diseases 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- 230000006933 amyloid-beta aggregation Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 210000004227 basal ganglia Anatomy 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000001072 heteroaryl group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 3
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 3
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 3
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229960004889 salicylic acid Drugs 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 125000000547 substituted alkyl group Chemical group 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 150000007970 thio esters Chemical class 0.000 description 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000002861 ventricular Effects 0.000 description 3
- 0 **N(*)c(cc1)cc(*)c1O Chemical compound **N(*)c(cc1)cc(*)c1O 0.000 description 2
- 206010000117 Abnormal behaviour Diseases 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000007546 Aβ plaque accumulation Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010067482 No adverse event Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 150000001409 amidines Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical compound [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- TYFQFVWCELRYAO-UHFFFAOYSA-N suberic acid Chemical compound OC(=O)CCCCCCC(O)=O TYFQFVWCELRYAO-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002636 symptomatic treatment Methods 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- QFKARHNGIMHMJI-UHFFFAOYSA-N 2-aminooxy-5-(4-nitrophenyl)sulfonylbenzoic acid Chemical compound C1=C(C(O)=O)C(ON)=CC=C1S(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 QFKARHNGIMHMJI-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- GMUFZBPDACVJNU-UHFFFAOYSA-N 3-acetamido-2-(2-hydroxyethyl)-5-[(4-nitrophenyl)methyl]benzoic acid Chemical compound OC(=O)C1=C(CCO)C(NC(=O)C)=CC(CC=2C=CC(=CC=2)[N+]([O-])=O)=C1 GMUFZBPDACVJNU-UHFFFAOYSA-N 0.000 description 1
- 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700114 Chinchillidae Species 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 241000289659 Erinaceidae Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000282339 Mustela Species 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229940099433 NMDA receptor antagonist Drugs 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 101710096361 Prostaglandin E synthase Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000001664 diethylamino group Chemical class [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 230000004590 drinking behavior Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-N ethanethioic S-acid Chemical class CC(S)=O DUYAAUVXQSMXQP-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003090 exacerbative effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 235000013666 improved nutrition Nutrition 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000013038 irreversible inhibitor Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001016 myotrophic effect Effects 0.000 description 1
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000009449 neurobehavioral function Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 231100000062 no-observed-adverse-effect level Toxicity 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- NEGYEDYHPHMHGK-UHFFFAOYSA-N para-methoxyamphetamine Chemical compound COC1=CC=C(CC(C)N)C=C1 NEGYEDYHPHMHGK-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 102220020162 rs397508045 Human genes 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- VYPDUQYOLCLEGS-UHFFFAOYSA-M sodium;2-ethylhexanoate Chemical compound [Na+].CCCCC(CC)C([O-])=O VYPDUQYOLCLEGS-UHFFFAOYSA-M 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Description
本出願は、参照することにより全体が本明細書に組み込まれる、2018年12月28日出願の米国仮特許出願第62/785,903号の利益及びそれに対する優先権を主張する。
本開示は、老齢のコンパニオンアニマルの認知障害を処置するための医薬組成物であって、式(I)の5-ベンジルアミノサリチル酸化合物又はその薬学的に許容される塩、及び経口投与に好適な薬学的に許容される賦形剤を含む医薬組成物に関する。本開示は、犬科のCDS、気分変調症(dysthymia)、退行期うつ病(involutive depression)及び錯乱症候群(confusional syndrome)を含む認知機能低下の処置の方法に関する。
5-ベンジルアミノサリチル酸化合物、又はその薬学的に許容される塩が、AD及び神経変性疾患の処置に使用されている(米国特許第6,964,982号)。以前の研究では、2-ヒドロキシ-5-[2-(4-トリフルオロメチル-フェニル)エチルアミノ]安息香酸が、ナノモル濃度で効果的な強力なスピントラップ分子及びミクロソームプロスタグランジンE(2)シンターゼ1(mPGES-1)阻害剤として検証されており、これは、筋萎縮性側索硬化症のマウスモデルにおける神経細胞死、軸索変性症及び自食胞形成の遮断だけでなく、運動機能活動及び生存期間の増加ももたらす[20]。
Xは、CO、SO2及び(CH2)nから選択され、
R1は、水素、C1~C6アルキル及びC1~C6アルカノイルから選択され、
R2は、水素及びC1~C6アルキルから選択され、
R3は、水素及びC1~C5アセチル基から選択され、
R4は、フェニル基、フェノキシ基、並びに置換されていない又はニトロ、ハロゲン、C1~C6アルキル、C1~C6ハロアルキル、C1~C5アルコキシ及びC1~C5ハロアルコキシからそれぞれ独立して選択される1つ以上の置換基で置換された5~10員アリール基から選択され、
nは、1~5(これらを含む)の整数である)の化合物、
又はその薬学的に許容される塩を提供する。
Xは、CO、SO2及び(CH2)nから選択され、
R1は、水素、C1~C6アルキル及びC1~C6アルカノイルから選択され、
R2は、水素及びC1~C6アルキルから選択され、
R3は、水素及びC1~C5アセチル基から選択され、
R4は、フェニル基、フェノキシ基、並びに置換されていない又はニトロ、ハロゲン、C1~C6アルキル、C1~C6ハロアルキル、C1~C5アルコキシ及びC1~C5ハロアルコキシからそれぞれ独立して選択される1つ以上の置換基で置換された5~10員アリール基から選択され、
nは、1~5(これらを含む)の整数である)の化合物、
又はその薬学的に許容される塩を投与するステップを含む方法を提供する。
以下に記載の用語の定義は、それ自体での、又は他の用語と組み合わせた用語の使用に適用され得る。
本開示はまた、上記化学式(I)で表される5-ベンジルアミノサリチル酸誘導体又はその薬学的に許容される塩、及び薬学的に許容される賦形剤又は添加剤を含む組成物を提供する。本開示の上記化学式(I)で表される5-ベンジルアミノサリチル酸誘導体又はその薬学的に許容される塩は、単独で投与されてもよい。いくつかの実施形態において、式(I)の化合物を含む組成物は、任意の便利な担体、希釈剤等と共に投与される。
約1mg~約1000mgの式(I)の化合物、
約50%w/w~約70%w/wのラクトース一水和物、
約2%w/w~約8%w/wのクロスカルメロースナトリウム、
約0.1%w/w~約1%w/wのステアリン酸マグネシウム、及び
約0.1%w/w~約2%w/wのラウリル硫酸ナトリウム
を含むカプセルである。
約1mg~約1000mgの式(I)の化合物、
約60%w/wのラクトース一水和物、
約5%w/wのクロスカルメロースナトリウム、
約0.5%w/wのステアリン酸マグネシウム、及び
約1%w/wのラウリル硫酸ナトリウム
を含むカプセルである。
約1mg~約1000mgの式(I)の化合物、
約30%w/w~約50%w/wのデンプン、
約15%w/w~約25%w/wの粗タンパク質、
約10%w/w~約20%の粗脂肪、
約0.1%w/w~約5%w/wの粗繊維、
約1%w/w~約10%w/wの粗灰分、
約0.1%w/w~約5%w/wのアルギニン、
約0.1%w/w~約2.5%w/wのカルシウム、
約0.1%w/w~約3%w/wのリシン、
約0.1%w/w~約3%w/wのメチオニン及びシスチン、並びに
約0.1%w/w~約2.5%w/wのリン
を含む食品組成物である。
約1mg~約1000mgの式(I)の化合物、
約42.7%w/wのデンプン、
約21.0%w/wの粗タンパク質、
約14%w/wの粗脂肪、
約1.9%w/wの粗繊維、
約6.1%w/wの粗灰分、
約1.4%w/wのアルギニン、
約0.75%w/wのカルシウム、
約1.1%w/wのリシン、
約1.18%w/wのメチオニン及びシスチン、並びに
約0.5%w/wのリン
を含む食品組成物である。
約1mg~約1000mgの式(I)の化合物、
約5%w/w~約20%w/wの粗タンパク質、
約0.1%w/w~約5%w/wの粗脂肪、
約0.1%w/w~約5%w/wの粗繊維、
約0.1%w/w~約5%w/wの粗灰分、
約0%w/w~約1%w/wのカルシウム、
約0%w/w~約2%w/wのカリウム、及び
約60%w/w~約95%w/wの水
を含む健康補助食品である。
約1mg~約1000mgの式(I)の化合物、
約12.0%w/wの粗タンパク質、
約1.5%w/wの粗脂肪、
約0.4%w/wの粗繊維、
約1.5%w/wの粗灰分、
約0.02%w/wのカルシウム、
約0.1%w/wのカリウム、及び
約78.0%w/wの水
を含む健康補助食品である。
約1mg~約1000mgの式(I)の化合物、
約0.1%w/w~約5%w/wの二酸化ケイ素、
約0%w/w~約2%w/wの安息香酸、
約0%w/w~約1%w/wのソルビン酸、
約0.1%w/w~約10%w/wのステアリン酸マグネシウム、
約10%w/w~約30%w/wのセルロース、
約30%w/w~約50%w/wの鶏肉源、
約0.1%w/w~約5%w/wの乾燥酵母、及び
約10%w/w~約30%w/wのグルコース
を含むチュアブル錠である。
約1mg~約1000mgの式(I)の化合物、
約3%w/wの二酸化ケイ素、
約0.05%w/wの安息香酸、
約0.01%w/wのソルビン酸、
約5%w/wのステアリン酸マグネシウム、
約20%w/wのセルロース、
約40%w/wの鶏肉粉末、
約3%w/wの乾燥酵母、及び
約19%w/wのグルコース
を含むチュアブル錠である。
化合物2の2-ヒドロキシ-5-[2-(4-トリフルオロメチル-フェニル)エチルアミノ]安息香酸を代表的化合物として使用した。以降では、当業者が本開示を理解する上での補助となるように、本開示を極めて詳細に記載する。しかしながら、以下の実施例は例示を目的として提供されるものであり、本開示の範囲を限定することを意図しない。本開示の精神及び範囲から逸脱することなく、又はその全ての重要な利点を犠牲にすることなく様々な変更がなされてもよいことは明らかである。
予備データでは、AD(APP/PS1マウス)及び筋萎縮性側索硬化症(G93Aマウス)の動物モデルにおいて、2.5mg/kgの用量での化合物2の経口投与後に最大限に有益な効果、例えば認知及び運動機能の改善が示された。
評価尺度は、CDS診断、病期分類、評価及び疾患症状の慎重なモニタリング、並びに治療戦略の有効性評価に不可欠なツールである。ここ10年の間、いくつかの評価尺度、例えばCCDR尺度が開発された[21~24]。この試験においてCDSの重症度を評価するために、獣医による化合物2の経口投与の前及び後に、2つの質問票(CCDR尺度及びCADES)を実施した。質問票は、食欲、水を飲む行動、咆哮、***行動、日中/夜間睡眠パターン、無目的の行動、適応能力、社会的行動、知覚力、失見当識及び記憶を測定する広範な項目を含む。
CCDR尺度は、CDS症状に基づく13の項目からなる(表2)。13種類の行動は、方向感覚(ぼんやり眺める、室内で道に迷う)、記憶(飼い主の認識の欠如、不適切な場所での***)、無関心(活動的である時間の低減、飼い主との接触を避ける)、嗅覚障害(食物を見つけるのが困難である)、及び運動に関連する様々な問題を含んでいた。これらの問題は、犬の生活の質及び犬と飼い主との絆の両方を悪化させる[25、26]。CCDRにおける50≧のスコアは、年老いた犬(12~19歳)のCDSを示している。この試験では、CDSに罹患した犬における化合物2の投与の前及び後のCCDRスコアを比較した。
CCDR尺度を保証及び確認するために、追加の質問票であるCADESを使用したが、これは、犬の行動の変化に関連する4つのドメイン:空間的方向感覚、社会的交流、睡眠-覚醒サイクル及び不適切な場所での***に分配された17の項目を含む(表6)[3]。これは、認知機能障害の様々な段階:軽度、中程度及び重度の認知機能障害に従って分類され得る。CADESはまた、犬科の認知機能障害の進行の長期的評価に、また潜在的に処置の有効性読取り情報として好適であることは周知である。
認知機能障害に対する化合物2の効果を明確化するために、CDSに罹患した5匹の犬(対象18~22)にプラセボを与えた。プラセボが与えられたほとんどの犬におけるCCDR及びCADESスコアは、プラセボ処置から8週間後に有意な変化又は増加を示さなかったが、これはプラセボ処置が認知機能に影響しなかったことを示している。全体的に、化合物2が犬科のCDSにおいて認知機能障害を低減するために投与され得ることが強く暗に示されている。
この試験の間、CDSに罹患した犬における化合物2の安全性を、受診する度に評価した。結果として、血液毒性テストにおける有意な変化は観察されず、処置関連有害事象もまた生じなかった。
2つの質問票を使用して、CDSに罹患したコンパニオンドッグにおける認知機能に対する化合物2の効果を評価した。CCDR尺度では、化合物2の投与は、ほぼ正常スコアまで認知機能を実質的に改善した。CCDR尺度と一致して、CDSに罹患した犬における重度の認知及び神経行動障害は、化合物2の投与後8週間以内に有意に軽減された。これらの有益な効果は、化合物2の8週間又は12週間投与が完了した後に、4週間又は8週間にわたり維持された。また、試験中、有害事象又は毒性は観察されなかった。一方、プラセボ群では有意な改善は見られなかった。総合すると、これらの所見は、化合物2が犬科、さらには猫科のCDSを処置するために適用され得ることを強く暗に示している。
1. Azkona, G., et al., Prevalence and risk factors of behavioural changes associated with age-related cognitive impairment in geriatric dogs. J Small Anim Pract, 2009. 50(2): p. 87-91.
2. Neilson, J.C., et al., Prevalence of behavioral changes associated with age-related cognitive impairment in dogs. J Am Vet Med Assoc, 2001. 218(11): p. 1787-91.
3. Madari, A., et al., Assessment of severity and progression of canine cognitive dysfunction syndrome using the CAnine DEmentia Scale (CADES). Appl Anim Behav Sci., 2015. 171: p. 138-45.
4. Salvin, H.E., et al., Under diagnosis of canine cognitive dysfunction: a cross-sectional survey of older companion dogs. The Veterinary Journal, 2010. 184(3): p. 277-281.
5. Hart, B.L. and L.A. Hart, Selecting, raising, and caring for dogs to avoid problem aggression. Journal of the American Veterinary Medical Association, 1997. 210(8): p. 1129.
6. Landsberg, G.M., J. Nichol, and J.A. Araujo, Cognitive dysfunction syndrome: a disease of canine and feline brain aging. Vet Clin North Am Small Anim Pract, 2012. 42(4): p. 749-68, vii.
7. Landsberg, G.M., T. Deporter, and J.A. Araujo, Clinical signs and management of anxiety, sleeplessness, and cognitive dysfunction in the senior pet. Vet Clin North Am Small Anim Pract, 2011. 41(3): p. 565-90.
8. Gonzalez-Martinez, A., et al., Effect of age and severity of cognitive dysfunction on two simple tasks in pet dogs. Vet J, 2013. 198(1): p. 176-81.
9. Cummings, B.J., et al., β-amyloid accumulation correlates with cognitive dysfunction in the aged canine. Neurobiology of learning and memory, 1996. 66(1): p. 11-23.
10. Cummings, B.J., et al., β-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiology of aging, 1996. 17(6): p. 921-933.
11. Cummings, B.J., et al., Diffuse plaques contain C-terminal Aβ42 and not Aβ40: evidence from cats and dogs. Neurobiology of aging, 1996. 17(4): p. 653-659.
12. Ozawa, M., et al., The Relation between canine cognitive dysfunction and age-related brain lesions. J Vet Med Sci, 2016. 78(6): p. 997-1006.
13. Rofina, J., et al., Cognitive disturbances in old dogs suffering from the canine counterpart of Alzheimer's disease. Brain research, 2006. 1069(1): p. 216-226.
14. Head, E., et al., Visual-discrimination learning ability and β-amyloid accumulation in the dog. Neurobiology of aging, 1998. 19(5): p. 415-425.
15. Tapp, P.D., et al., Frontal lobe volume, function, and β-amyloid pathology in a canine model of aging. Journal of Neuroscience, 2004. 24(38): p. 8205-8213.
16. Druce, K., Canine cognitive dysfunction-recognition and treatment. Veterinary Nursing Journal, 2014. 29(8): p. 268-270.
17. Ruehl, W., et al., Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy, in Progress in Brain Research. 1995, Elsevier. p. 217-225.
18. Head, E., et al., Spatial learning and memory as a function of age in the dog. Behavioral neuroscience, 1995. 109(5): p. 851.
19. Campbell, S., A. Trettien, and B. Kozan, A noncomparative open-label study evaluating the effect of selegiline hydrochloride in a clinical setting. Vet Ther, 2001. 2(1): p. 24-39.
20. Shin, J.H., et al., Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. Journal of neurochemistry, 2012. 122(5): p. 952-961.
21. Colle, M.A., et al., Vascular and parenchymal Abeta deposition in the aging dog: correlation with behavior. Neurobiol Aging, 2000. 21(5): p. 695-704.
22. Pugliese, M., et al., Severe cognitive impairment correlates with higher cerebrospinal fluid levels of lactate and pyruvate in a canine model of senile dementia. Prog Neuropsychopharmacol Biol Psychiatry, 2005. 29(4): p. 603-10.
23. Schneider, B.M. and M.H. Erhard, [Canine cognitive dysfunction syndrome: prevalence, diagnosis and therapeutic measures]. Tierarztl Prax Ausg K Kleintiere Heimtiere, 2010. 38(2): p. 113-8.
24. Salvin, H.E., et al., The canine cognitive dysfunction rating scale (CCDR): a data-driven and ecologically relevant assessment tool. Vet J, 2011. 188(3): p. 331-6.
25. Hughes, C.P., et al., A new clinical scale for the staging of dementia. Br J Psychiatry, 1982. 140: p. 566-72.
26. Swan, G.E. and D. Carmelli, Impaired olfaction predicts cognitive decline in nondemented older adults. Neuroepidemiology, 2002. 21(2): p. 58-67.
Claims (20)
- 式(I):
Xは、CO、SO2及び(CH2)nから選択され、
R1は、水素、C1~C6アルキル及びC1~C6アルカノイルから選択され、
R2は、水素及びC1~C6アルキルから選択され、
R3は、水素及びC1~C5アセチル基から選択され、
R4は、フェニル基、フェノキシ基、並びに置換されていない又はニトロ、ハロゲン、C1~C6アルキル、C1~C6ハロアルキル、C1~C5アルコキシ及びC1~C5ハロアルコキシからなる群のうちの1つ以上で置換された5~10員アリール基から選択され、
nは、1~5(これらを含む)の整数である)の化合物、
又はその薬学的に許容される塩、並びに
例えば経口投与に好適な薬学的に許容される賦形剤を含む組成物。 - 式(I)の化合物が、2-ヒドロキシ-5-フェネチルアミノ-安息香酸、2-ヒドロキシ-5-[2-(4-トリフルオロメチル-フェニル)-エチルアミノ]-安息香酸、2-ヒドロキシ-5-[2-(3-トリフルオロメチル-フェニル)-エチルアミノ]-安息香酸、5-[2-(3,5-ビス-トリフルオロメチル-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、2-ヒドロキシ-5-[2-(2-ニトロ-フェニル)-エチルアミノ]-安息香酸、5-[2-(4-クロロ-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、5-[2-(3,4-ジフルオロ-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、5-[2-(3,4-ジクロロ-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、5-[2-(4-フルオロ-2-トリフルオロメチル-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、5-[2-(2-フルオロ-4-トリフルオロメチル-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、2-ヒドロキシ-5-[2-(4-メトキシ-フェニル)-エチルアミノ]-安息香酸、2-ヒドロキシ-5-(2-o-トリル-エチルアミノ)-安息香酸、2-ヒドロキシ-5-(3-フェニル-プロピルアミノ)-安息香酸、2-ヒドロキシ-5-[3-(4-トリフルオロメチル-フェニル)-プロピルアミノ]-安息香酸、5-[3-(4-フルオロ-フェニル)-プロピルアミノ]-2-ヒドロキシ-安息香酸、5-[3-(3,4-ジクロロ-フェニル)-プロピルアミノ]-2-ヒドロキシ-安息香酸、2-ヒドロキシ-5-(3-p-トリル-プロピルアミノ)-安息香酸、2-アセトキシ-5-[2-(4-トリフルオロメチル-フェニル)-エチルアミノ]-安息香酸、5-[2-(2-クロロ-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、5-ベンジルアミノサリチル酸、5-(4-ニトロベンジル)アミノサリチル酸、5-(4-クロロベンジル)アミノサリチル酸、5-(4-トリフルオロメチルベンジル)アミノサリチル酸、5-(4-フルオロベンジル)アミノサリチル酸、5-(4-メトキシベンジル)アミノサリチル酸、5-(2,3,4,5,6-ペンタフルオロベンジル)アミノサリチル酸、5-(4-ニトロベンジル)アミノ-2-ヒドロキシエチルベンゾエート、5-(4-ニトロベンジル)-N-アセチルアミノ-2-ヒドロキシエチルベンゾエート、5-(4-ニトロベンジル)-N-アセチルアミノ-2-アセトキシエチルベンゾエート、5-(4-ニトロベンゾイル)アミノサリチル酸、5-(4-ニトロベンゼンスルホニル)アミノサリチル酸、5-[2-(4-ニトロフェニル)-エチル]アミノサリチル酸、及び5-[3-(4-ニトロ-フェニル)-n-プロピル]アミノサリチル酸からなる群から選択される、請求項1に記載の組成物。
- 式(I)の化合物が、2-ヒドロキシ-5-[2-(4-トリフルオロメチル-フェニル)-エチルアミノ]-安息香酸である、請求項2に記載の組成物。
- 1mg~1000mgの式(I)の化合物又はその薬学的に許容される塩を含む、請求項1から3のいずれか一項に記載の組成物。
- 1mg~1000mgの式(I)の化合物、
60%w/wのラクトース一水和物、
5%w/wのクロスカルメロースナトリウム、
0.5%w/wのステアリン酸マグネシウム、及び
1%w/wのラウリル硫酸ナトリウム
を含むカプセルである、請求項1から4のいずれか一項に記載の組成物。 - 1mg~1000mgの式(I)の化合物、
42.7%w/wのデンプン、
21.0%w/wの粗タンパク質、
14%w/wの粗脂肪、
1.9%w/wの粗繊維、
6.1%w/wの粗灰分、
1.4%w/wのアルギニン、
0.75%w/wのカルシウム、
1.1%w/wのリシン、
1.18%w/wのメチオニン及びシスチン、並びに
0.5%w/wのリン
を含む食品組成物である、請求項1から4のいずれか一項に記載の組成物。 - 1mg~1000mgの式(I)の化合物、
12.0%w/wの粗タンパク質、
1.5%w/wの粗脂肪、
0.4%w/wの粗繊維、
1.5%w/wの粗灰分、
0.02%w/wのカルシウム、
0.1%w/wのカリウム、及び
78.0%w/wの水
を含む健康補助食品である、請求項1から4のいずれか一項に記載の組成物。 - 1mg~1000mgの式(I)の化合物、
3%w/wの二酸化ケイ素、
0.05%w/wの安息香酸、
0.01%w/wのソルビン酸、
5%w/wのステアリン酸マグネシウム、
20%w/wのセルロース、
40%w/wの鶏肉源、
3%w/wの乾燥酵母、及び
19%w/wのグルコース
を含むチュアブル錠である、請求項1から4のいずれか一項に記載の組成物。 - 酸化ストレス及び炎症の同時薬理学的阻害により認知機能不全症候群(CDS)を処置するための医薬の製造のための、請求項1から8のいずれか一項に記載の組成物の使用。
- 酸化ストレス及びプロスタグランジンE2合成の阻害によりCDSを処置するための医薬の製造のための、請求項1から8のいずれか一項に記載の化合物の使用。
- 酸化ストレス及びミクロソームプロスタグランジンEシンターゼ1の阻害によりCDSを処置するための医薬の製造のための、請求項1から8のいずれか一項に記載の化合物の使用。
- 例えば神経疾患における、認知及び/又は神経行動障害を処置する方法であって、それを必要とするコンパニオンアニマルに、式(I):
Xは、CO、SO2及び(CH2)nから選択され、
R1は、水素、C1~C6アルキル及びC1~C6アルカノイルから選択され、
R2は、水素及びC1~C6アルキルから選択され、
R3は、水素及びC1~C5アセチル基から選択され、
R4は、フェニル基、フェノキシ基、並びに置換されていない又はニトロ、ハロゲン、C1~C6アルキル、C1~C6ハロアルキル、C1~C5アルコキシ及びC1~C5ハロアルコキシからなる群のうちの1つ以上で置換された5~10員アリール基から選択され、
nは、1~5(これらを含む)の整数である)の化合物、
又はその薬学的に許容される塩を投与するステップを含む方法。 - 式(I)の化合物が、2-ヒドロキシ-5-フェネチルアミノ-安息香酸、2-ヒドロキシ-5-[2-(4-トリフルオロメチル-フェニル)-エチルアミノ]-安息香酸、2-ヒドロキシ-5-[2-(3-トリフルオロメチル-フェニル)-エチルアミノ]-安息香酸、5-[2-(3,5-ビス-トリフルオロメチル-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、2-ヒドロキシ-5-[2-(2-ニトロ-フェニル)-エチルアミノ]-安息香酸、5-[2-(4-クロロ-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、5-[2-(3,4-ジフルオロ-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、5-[2-(3,4-ジクロロ-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、5-[2-(4-フルオロ-2-トリフルオロメチル-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、5-[2-(2-フルオロ-4-トリフルオロメチル-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、2-ヒドロキシ-5-[2-(4-メトキシ-フェニル)-エチルアミノ]-安息香酸、2-ヒドロキシ-5-(2-o-トリル-エチルアミノ)-安息香酸、2-ヒドロキシ-5-(3-フェニル-プロピルアミノ)-安息香酸、2-ヒドロキシ-5-[3-(4-トリフルオロメチル-フェニル)-プロピルアミノ]-安息香酸、5-[3-(4-フルオロ-フェニル)-プロピルアミノ]-2-ヒドロキシ-安息香酸、5-[3-(3,4-ジクロロ-フェニル)-プロピルアミノ]-2-ヒドロキシ-安息香酸、2-ヒドロキシ-5-(3-p-トリル-プロピルアミノ)-安息香酸、2-アセトキシ-5-[2-(4-トリフルオロメチル-フェニル)-エチルアミノ]-安息香酸、5-[2-(2-クロロ-フェニル)-エチルアミノ]-2-ヒドロキシ-安息香酸、5-ベンジルアミノサリチル酸、5-(4-ニトロベンジル)アミノサリチル酸、5-(4-クロロベンジル)アミノサリチル酸、5-(4-トリフルオロメチルベンジル)アミノサリチル酸、5-(4-フルオロベンジル)アミノサリチル酸、5-(4-メトキシベンジル)アミノサリチル酸、5-(2,3,4,5,6-ペンタフルオロベンジル)アミノサリチル酸、5-(4-ニトロベンジル)アミノ-2-ヒドロキシエチルベンゾエート、5-(4-ニトロベンジル)-N-アセチルアミノ-2-ヒドロキシエチルベンゾエート、5-(4-ニトロベンジル)-N-アセチルアミノ-2-アセトキシエチルベンゾエート、5-(4-ニトロベンゾイル)アミノサリチル酸、5-(4-ニトロベンゼンスルホニル)アミノサリチル酸、5-[2-(4-ニトロフェニル)-エチル]アミノサリチル酸、及び5-[3-(4-ニトロ-フェニル)-n-プロピル]アミノサリチル酸からなる群から選択される、請求項12に記載の方法。
- 式(I)の化合物が、2-ヒドロキシ-5-[2-(4-トリフルオロメチル-フェニル)-エチルアミノ]-安息香酸である、請求項13に記載の方法。
- 2-ヒドロキシ-5-[2-(4-トリフルオロメチル-フェニル)-エチルアミノ]-安息香酸が、1mg/kg体重~200mg/kg体重の用量で1日1回投与される、請求項12に記載の方法。
- 組成物を投与するステップを含み、組成物は、
1mg~1000mgの式(I)の化合物、
60%w/wのラクトース一水和物、
5%w/wのクロスカルメロースナトリウム、
0.5%w/wのステアリン酸マグネシウム、及び
1%w/wのラウリル硫酸ナトリウム
を含むカプセルである、請求項12に記載の方法。 - 組成物を投与するステップを含み、組成物は、
1mg~1000mgの式(I)の化合物、
42.7%w/wのデンプン、
21.0%w/wの粗タンパク質、
14%w/wの粗脂肪、
1.9%w/wの粗繊維、
6.1%w/wの粗灰分、
1.4%w/wのアルギニン、
0.75%w/wのカルシウム、
1.1%w/wのリシン、
1.18%w/wのメチオニン及びシスチン、並びに
0.5%w/wのリン
を含む食品組成物である、請求項12に記載の方法。 - 組成物を投与するステップを含み、組成物は、
1mg~1000mgの式(I)の化合物、
12.0%w/wの粗タンパク質、
1.5%w/wの粗脂肪、
0.4%w/wの粗繊維、
1.5%w/wの粗灰分、
0.02%w/wのカルシウム、
0.1%w/wのカリウム、及び
78.0%w/wの水
を含む健康補助食品である、請求項12に記載の方法。 - 組成物を投与するステップを含み、組成物は、
1mg~1000mgの式(I)の化合物、
3%w/wの二酸化ケイ素、
0.05%w/wの安息香酸、
0.01%w/wのソルビン酸、
5%w/wのステアリン酸マグネシウム、
20%w/wのセルロース、
40%w/wの鶏肉源、
3%w/wの乾燥酵母、及び
19%w/wのグルコース
を含むチュアブル錠処方である、請求項12に記載の方法。 - 認知及び/又は神経行動障害が、認知機能不全症候群、気分変調症、退行期うつ病及び錯乱症候群から選択される、請求項12から19のいずれか一項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785903P | 2018-12-28 | 2018-12-28 | |
US62/785,903 | 2018-12-28 | ||
PCT/IB2019/001409 WO2020136441A1 (en) | 2018-12-28 | 2019-12-26 | Compositions and methods for treating neurodegenerative disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022515520A true JP2022515520A (ja) | 2022-02-18 |
JPWO2020136441A5 JPWO2020136441A5 (ja) | 2023-01-10 |
Family
ID=71121937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021538053A Pending JP2022515520A (ja) | 2018-12-28 | 2019-12-26 | 神経変性障害を処置するための組成物及び処置する方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US20200206172A1 (ja) |
EP (1) | EP3902536A4 (ja) |
JP (1) | JP2022515520A (ja) |
KR (1) | KR20210107828A (ja) |
CN (1) | CN113710242A (ja) |
AU (1) | AU2019412533A1 (ja) |
BR (1) | BR112021012707A2 (ja) |
CA (1) | CA3124767A1 (ja) |
MX (1) | MX2021007780A (ja) |
PH (1) | PH12021551541A1 (ja) |
WO (1) | WO2020136441A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102454371B1 (ko) * | 2019-07-08 | 2022-10-14 | 주식회사 지엔티파마 | 5-벤질아미노살리실산 유도체를 포함하는 화장품 조성물 및 이의 국소 사용방법 |
CN113735726A (zh) * | 2021-08-09 | 2021-12-03 | 浙江理工大学 | 一种2-羟基-5-[2-(4-(三氟甲基苯基)乙基氨基)]苯甲酸钠及其制备方法 |
WO2023156808A2 (en) * | 2021-12-28 | 2023-08-24 | Gnt Pharma Co., Ltd. | Compositions and methods for treating pulmonary disorders |
CN114414332B (zh) * | 2022-01-05 | 2024-04-16 | 北京科技大学 | 一种基于Al-CQDs和Al-CNSs的抗氧化剂的制备方法 |
KR102517992B1 (ko) | 2022-05-26 | 2023-04-05 | 주식회사 에이엘 네트웍스 | 인지장애 및 뇌기능 개선을 위한 펫푸드 조성물 및 이의 제조 방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1196348B (it) * | 1984-11-29 | 1988-11-16 | Italfarmaco Spa | Composti ad attivita'antiinfiammatoria |
WO1994013663A1 (en) * | 1992-12-10 | 1994-06-23 | Pfizer Inc. | Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists |
AU2003245070C1 (en) * | 2002-06-19 | 2008-02-28 | GNT Pharma Co., Ltd | Tetrafluorobenzyl derivatives and pharmaceutical composition for preventing and treating acute and chronic neurodegenerative diseases in central nervous system containing the same |
KR100522187B1 (ko) * | 2002-10-18 | 2005-10-18 | 주식회사 뉴로테크 | 중추신경계의 급성 및 만성적 손상에 기인한 신경세포의퇴화를 방지하기 위한 화합물, 조성물 및 방법 |
US20070298129A1 (en) * | 2005-08-24 | 2007-12-27 | Neurotech Pharmaceuticals Co., Ltd. | Compounds and compositions for treating neuronal death or neurological dysfunction |
KR101204108B1 (ko) * | 2009-02-09 | 2012-11-22 | 주식회사 지엔티파마 | 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도 |
PL2732818T3 (pl) * | 2009-03-31 | 2017-12-29 | Ligand Pharmaceuticals Inc. | Bifenylosulfonamidowy antagonista receptora endoteliny i angiotensyny II do leczenia stwardnienia kłębków nerkowych |
KR101646701B1 (ko) * | 2009-12-29 | 2016-08-08 | 주식회사 지엔티파마 | 에틸아미노 벤조산 유도체의 치료 용도 |
-
2019
- 2019-12-26 CA CA3124767A patent/CA3124767A1/en active Pending
- 2019-12-26 WO PCT/IB2019/001409 patent/WO2020136441A1/en unknown
- 2019-12-26 CN CN201980090544.2A patent/CN113710242A/zh active Pending
- 2019-12-26 KR KR1020217023878A patent/KR20210107828A/ko unknown
- 2019-12-26 AU AU2019412533A patent/AU2019412533A1/en active Pending
- 2019-12-26 BR BR112021012707-0A patent/BR112021012707A2/pt unknown
- 2019-12-26 EP EP19903186.5A patent/EP3902536A4/en active Pending
- 2019-12-26 JP JP2021538053A patent/JP2022515520A/ja active Pending
- 2019-12-26 US US16/727,577 patent/US20200206172A1/en not_active Abandoned
- 2019-12-26 MX MX2021007780A patent/MX2021007780A/es unknown
-
2021
- 2021-06-28 PH PH12021551541A patent/PH12021551541A1/en unknown
-
2022
- 2022-04-19 US US17/723,828 patent/US20220241231A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20210107828A (ko) | 2021-09-01 |
MX2021007780A (es) | 2021-12-15 |
WO2020136441A1 (en) | 2020-07-02 |
US20220241231A1 (en) | 2022-08-04 |
US20200206172A1 (en) | 2020-07-02 |
EP3902536A4 (en) | 2022-09-28 |
PH12021551541A1 (en) | 2022-02-28 |
BR112021012707A2 (pt) | 2021-09-08 |
EP3902536A1 (en) | 2021-11-03 |
CN113710242A (zh) | 2021-11-26 |
CA3124767A1 (en) | 2020-07-02 |
AU2019412533A1 (en) | 2021-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022515520A (ja) | 神経変性障害を処置するための組成物及び処置する方法 | |
US10434109B2 (en) | Compositions for treating neurological disorders | |
EP2680836B1 (en) | New compositions for treating neurological disorders | |
US9211294B2 (en) | Phenothiazine compounds for treating mild cognitive impairment | |
US9931326B2 (en) | Composition comprising torasemide and baclofen for treating neurological disorders | |
US20050096395A1 (en) | Methods of treating attention deficit/hyperactivity disorder (adhd) | |
EP2004176B1 (en) | USE OF N- ( DIBENZ (b, f) OXEPIN-10-YLMETHYL ) N-METHYL-N- PROP- 2 -YNYLAMINE (OMIGAPIL) FOR THE PROPHYLAXIS AND / OR TREATMENT OF CONGENITAL MUSCULAR DYSTROPHY OR MYOPATHY RESULTING FROM COLLAGEN VI DEFICIENCY | |
US20230098944A1 (en) | Method of decreasing amyloid beta monomer levels in patients with cognitive decline | |
JP2023506480A (ja) | アルツハイマー病の治療のための化合物 | |
JPWO2020136441A5 (ja) | ||
WO2020064857A1 (en) | Compounds that enhance the action of metformin | |
JP2020518562A (ja) | アルツハイマー病のイダロピルジン系組合せ療法 | |
CN102300573A (zh) | [2.2.2]双环衍生物及其使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20220809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20220809 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221226 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231212 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240312 |